Journal of Cystic Fibrosis

Article	Citations
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	141
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	129
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	124
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	120
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	106
260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	95
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	89
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	82
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	81
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	79
490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	77
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	73
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	70
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	68
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	66
529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	64
644 Timely initiation of pancreatic enzyme replacement therapy for surgical cystic fibrosis infants in the neonatal intensive care unit	60
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	59
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	59
480 Weight stigma among healthcare professionals treating CF in North America	55
Improved early growth in Danish children with cystic fibrosis from 2000-2022	52
WS13.01 The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis	51
Restoring airway epithelial homeostasis in Cystic Fibrosis	51
Autoimmunity in people with cystic fibrosis	48
203 Airway dysanapsis is associated with residual pulmonary exacerbation risk in children with cystic fibrosis treated with elexacaftor/tezacaftor/ ivacaftor	47

78 Pseudomonas aeruginosa induced GM-CSF production by airway epithelial cells could help protect against Mycobacterium abscessus	47
227 Nascent chain misfolding slows translation and stimulates co- translational mRNA decay	47
325 Evaluation of CFTR gene editing efficacy using patient-derived nose- on-chip model	47
97 Separability of membrane permeabilization and cell killing activities of the human host defense peptide LL-37 in Pseudomonas aeruginosa	45
346 Leaky gut, dysbiosis, and inflammation support inter-organ communication in cystic fibrosis	44
748 Development of metabolic syndrome in people with cystic fibrosis after three years of elexacaftor/tezacaftor/ivacaftor	42
258 Functional correction of CFTR-G542X in human bronchial epithelial cells using a Type I CRISPR adenine base editor with a guide-length- tunable editing window	40
41 Loss of MexEF-OprN function increases virulence of clinical Pseudomonas aeruginosa isolates	39
523 Navigating school with cystic fibrosis: perspectives of people with CF and their caregivers	39
634 Evaluating shared decision making in lung transplant discussions between clinicians and people with severe CF	38
729 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study	37
379 Identifying and prioritizing burdens of cystic fibrosis care for Canadians living with CF	37
241 Functional characterization of an ex vivo ferret model as a precursor for cell therapy	36
757 The impacts of highly effective modulator therapy and telehealth on cystic fibrosis care: Changes in visit frequency	36
475 Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age	35
786 Use of aerobic exercise for airway clearance in a pediatric CF care center	34
496 Pilot and feasibility study of an individualized telehealth exercise program in CF patients	34
279 Simultaneous inhibition of DNA-PKcs and 53BP1 enables the enrichment-free replacement of the CFTR cDNA in airway basal stem cells	32
48 Small airway epithelial cells in M. abscessus infection: Implications for inflammation and epithelial barrier integrity	32
22 The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies	31
34 Regulation of an epoxide-based virulence factor in Pseudomonas aeruginosa	31
252 Model systems to define tool LNP vehicles for the development of next generation therapies for Cystic Fibrosis	31
652 Proteomics of bronchoalveolar lavage fluid in cystic fibrosis ferrets spontaneously colonized by Pseudomonas aeruginosa	31
165 IL-21 and IL-21R interaction plays a key role in mounting humoral and cell-mediated immune response to adenoviral and adeno-associated viral vectors in lung	30
P352 Effect of ACE, ACTN3, PPARA, PPARGC1A gene polymorphisms on nutritional status in patients with cystic fibrosis in the Russian Federation	29
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre	29
P104 CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	28
WS10.02Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elexecaftor/tezacaftor/ivacaftor - The RECOVER study	27
P081 Elezacaftor/tezacaftor/ivacaftor therapy and quality of life in children and their caregivers	27
P174 A retrospective review of lung ultrasound in guiding physiotherapy input for people with cystic fibrosis in an in-patient setting	26
P159 Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society	26
WS14.01Primary nasal epithelial cells for personalized medicine in non-eligible cystic fibrosis patients	26
P223 The role of horizontal Gene transfer in the development of resistance in Achromobacter ruhlandii	26
P118 Community engagement and involvement in clinical trials and beyond…	26
P278 Trends in paediatric bone mineral density 2016-2024 – a single centre study	26
P308 Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycaemic control in children with cystic fibrosis: a promising trend towards improved glucose regulation	25
P418 Recalibrating “a whole new life”: exploring the impact of elexacaftor/tezacaftor/ivacaftor on self-concept for adults with cystic fibrosis	25
P421 Accessing impact of elexacaftor/tezacaftor/ivacaftor therapy on antidepressant usage in an adult cystic fibrosis population	25
P341 Body composition and handgrip strength among children and adolescents with cystic fibrosis: correlation with anthropometric parameters and disease severity	25
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation	24
P033 The impact of newborn bloodspot screening program modification in 2023 on the time of diagnosis in cystic fibrosis patients and follow-up care	24
P249 Aspergillus fumigatus prevalence in Georgian paediatric cystic fibrosis patients	24
P046 Investigating the safety of elexacaftor/tezacaftor/ivacaftor exposure during early development	24
257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator	23
ePS2.02 Comparison of FEV on a remote spirometry device with hospital software in an adult cystic fibrosis cohort	23
ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics	23
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis	22
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	22
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	22
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA	22

P083 Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections	22
P143 Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study	22
P106 Upper airway disease in adults with cystic fibrosis: a cross-sectional study	21
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK	21
145 Prescription of elexacaftor/tezacaftor/ ivacaftor in lung transplant recipients with cystic fibrosis	21
447 Mucociliary interactions and the vertical clearance assay 2.0	20
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis	20
51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry	19
P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	19
332 Vocational rehabilitation services for people with cystic fibrosis: Predictors of employment outcomes	19
419 Role of macrophage cystic fibrosis transmembrane conductance regulator in lung inflammation	19
P418 Patient satisfaction and clinical effectiveness of using the I-neb in children with cystic fibrosis (CF) in Wales	19
341 Improving care for pregnant people with cystic fibrosis by increasing knowledge of obstetric providers	18
348 Single-cell multi-omics profiling reveals novel regulatory networks of CFTR in the kidney	18
P387 Reviews and outcomes from a new pregnancy support service at a large cystic fibrosis centre	18
P243 The effect of hypoxic conditions on Burkholderia cenocepacia clinical isolates from individuals with cystic fibrosis	18
P282 Implementing routine assessment of gastrointestinal outcome measures in the cystic fibrosis clinic	18
132 Respiratory symptom changes during menstrual cycles in women with cystic fibrosis	18
487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis	18
59 Improving mycobacterial sputum culture collection in adult patients during the highly effective modulator therapy era	18
P360 Mental health in cystic fibrosis patients: predictive factors and psychopathology	18
633 Extracellular vesicles as delivery vectors to enhance killing of bacteria and viruses by airway-recruited human neutrophils	18
100 Vancomycin demonstrates activity against Mycobacterium abscessus in combination with guideline-recommended antibiotics under physiologically relevant stress conditions	17
249 Pharmacological rescue of CFTR premature termination codon mutations by novel small molecules	17
417 Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction	17
558 Development of a gene editing strategy to treat cystic fibrosisassociated liver disease	17
WS19.01 Non-adherence in the twilight zone: the complexity of complex medications	17
P295 The results of colorectal cancer screening in patients with cystic fibrosis in Wales	17
WS06.03 A real-world evaluation of remote monitoring in cystic fibrosis care: a mixed-methods multicentre observational study	17
329 Intrinsic conformational dynamics required for CFTR gating cycle revealed by single-molecule Förster resonance energy transfer	17
P007 Experience of using intestinal current measurement (ICM) in Russia	17
P104 The dynamics of health of children with cystic fibrosis in Russian Federation according to the registry data during last 10 years	17
43 Bacteriophages that kill Pseudomonas aeruginosa induce heterogenous cellular responses in the airway epithelium	16
P169 Vitamin absorption after the introduction of elexacaftor/tezacaftor/ivacaftor in children and adolescents diagnosed with cystic fibrosis	16
P017 The role of the VDR gene in the formation of clinical manifestations and complications in cystic fibrosis	16
624 Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness	16
P382 Cystic fibrosis and disordered eating behaviour: a collaborative approach to improve care	16
P134 Evaluation of multidisciplinary ambulatory care cost among children with cystic fibrosis: a comparative study between cystic fibrosis centers in Ireland and the United States	16
260 Cystic fibrosis transmembrane conductance regulator modulator–associated liver inflammation in pediatric cystic fibrosis	16
647 Impact of newborn screening program with NextGen sequencing on direct patient care	15
292 Mechanism of CFTR modulation on endothelial mechanosensitive channels	15
288 CFTR genetic variants and association with cancer	15
13 Extended-interval dosing of amikacin against Mycobacterium abscessus reduces efficacy in vitro	15
314 A role for CFTR in pancreatitis	15
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	15
P219 Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience	15
11 Examining antibiotic regimen spectrum and clinical outcomes of pulmonary exacerbation treatment	15
410 Multidisciplinary collaboration for transition readiness and planning	14
Neurovascular complications post bronchial artery embolisation in patients with cystic fibrosis. A 7-year single centre retrospective review	14
EPS5.08 Elexacaftor/tezacaftor/ ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study	14
Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor	14
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	14
462 Cystic fibrosis mental health and wellness questionnaire—factors and properties	14
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation	14
291 Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress	14
54 Recombinant pyocins as emerging therapies against respiratory infections with Pseudomonas aeruginosa	14
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	14
372 Cystic fibrosis does exist in India! A successful approach to education and improving awareness of cystic fibrosis of physicians and caregivers in India	14
Structure basis of CFTR folding, function and pharmacology	14
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort	13
Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor	13
Using heart rate data from wrist worn activity trackers to define thresholds for moderate to vigorous physical activity in children and young people with cystic fibrosis	13
Theranostics vs theratyping or theranostics plus theratyping?	13
Contents	13
Bone health after 3 years of ETI therapy: a real-world study from the Danish cystic fibrosis cohort	13
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance	13
P379 TIDES 2.0: prevalence and longitudinal course of depression, anxiety, and behaviour problems in children with cystic fibrosis (CF) under 12 years of age	13
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location	13
Sexual and reproductive health experiences and care of adult women with cystic fibrosis	13
The diagnostic challenge of pancreatic cysts in patients with cystic fibrosis: a case series and review of the literature	13
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol	13
Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis	13
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas	13
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	12
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	12
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	12
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	12
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	12
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	12
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	12

P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	12
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	12
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	12
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	12
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	12
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	12
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	12
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	12
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	12
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	12
628 Esophagogastroduodenoscopy findings in adults with cystic fibrosis: implications for screening and management	11
693 Machine learning analysis of continuous glucose monitoring after elexacaftor/tezacaftor/ivacaftor initiation in young children predicts dysglycemia better than an oral glucose tolerance test	11
489 Journey mapping of barriers to transitioning to adult CF care	11
CFTR-beyond the airways: Recent findings on the role of the CFTR channel in the pancreas, the intestine and the kidneys	11
45 Development of a co-culture model for secondary screening of candidate anti-microbial compounds targeting persistent lung infections in cystic fibrosis	11
470 Implementing annual collection of self-reported patient demographic information	11
ePS2.04 Is tele-physiotherapy as effective as home-visit-guided physiotherapy among children with cystic fibrosis?	11
469 Impact of social complexity on long-term health outcomes and survival in young adults with cystic fibrosis	11
326 Generation of a robust CFTR-specific immunolabeling protocol	11
Contents	11
513 Elexacaftor/tezacaftor/ivacaftor dose reduction leads to resolution of clinical adverse events without a significant effect on sweat chloride or FEV1	11
551 Integration of psychosocial screening tool into routine care of children with CF: Results of a 1-year pilot study and lessons learned	11
65 Thymic stromal lymphopoietin and IL-33 alarmin cytokine production by primary human cystic fibrosis lung macrophages is induced by infection with Pseudomonas aeruginosa and further increased by CFT	11
330 Rescue of CFTR nonsense mutations is enhanced under inflammatory stimuli	11
344 Transgene expression and CFTR channel function in human bronchial epithelial cells after addition of CFTR modulators and 4D-710	10
211 Characterization of airway submucosal gland hypertrophy in cystic fibrosis	10
207 Enhancing apical loop currents in airway epithelia carrying minimal function CFTR mutations	10
87 Activity of β-lactams and new β-lactamase inhibitors in multidrug-resistant Burkholderia contaminans	10
636 Characterizing use of acid-suppressing medications and foregut gastrointestinal testing in advanced cystic fibrosis lung disease in cystic fibrosis centers	10
75 Improvements in nutritional status, lung function, and respiratory cultures in pediatric cystic fibrosis after starting elexacaftor/tezacaftor/ivacaftor therapy: A real-world, multicenter study	10
403 Exploring CFTR variants: implications for exocrine pancreatic diseases	10
309 Pulmonary ionocytes regulate chloride secretion and absorption via CFTR	10
817 Harnessing the power of the electronic medical record to implement the new cystic fibrosis liver disease guidelines	10
308 Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs	10
716 Pilot screening prediction model for late-diagnosed cystic fibrosis	10
233 Altered role of septins in Pseudomonas aeruginosa intracellular infection of cystic fibrosis bronchial epithelial cells	10
182 IL-21R and IL-21 play a crucial role in modulating B and T cell immune responses to viral gene therapy vectors in the lungs	10
650 Single-center cohort study evaluating quality of colonoscopy bowel preparation in adults with cystic fibrosis	10
394 Elexacaftor/tezacaftor/ivacaftor interferes with hippocampal neurotransmission in mice	10
P274 Muddying the waters with menopause! How important is addressing the menopause in terms of cystic fibrosis care: Antibiotics or hormone replacement therapy?	10
4 Within-lung interspecies gene transfer causes rapid evolution of extreme antibiotic resistance in cystic fibrosis	10
865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF	10
680 Effects of elexacaftor/tezacaftor/ivacaftor on growth and puberty in children with cystic fibrosis	10
183 Adenylate cyclase 6 is required for cyclic adenosine monophosphate–dependent activation of CFTR to regulate mucociliary clearance in cystic fibrosis airways	10
607 Evidence of protease dose-response in a Phase 1 trial of ANG003, a non-porcine pancreatic enzyme replacement therapy	10
49 Differential effects of cationic antimicrobials on intrinsic antibiotic resistance in Pseudomonas aeruginosa	10
38 ACE-1b, a novel anti-infective conjugated electrolyte, effectively controls nontuberculous mycobacterial infections	10
P439 The role of the Research Play Specialist in CF Clinic, helping children and adolescents to develop coping strategies to overcome some of their anxieties in relation to blood sampling and beyond	10
P345 Increasing prevalence of pancreatic sufficiency in a paediatric CF unit – are CFTR modulators the cause?	10
EPS4.02Impact of ETI therapy on liver stiffness: a longitudinal study in children and adults	9
P285 Assessing potential of FIB-4 index and transient elastography for use in an adult cystic fibrosis population	9
WS08.02Specific Pseudomonas aeruginosa IgG levels before and after elexacaftor/tezacaftor/ivacaftor treatment	9
P453 A study on patient and healthcare provider experiences with outpatient sexual and reproductive healthcare for adults with cystic fibrosis: insights from a single-center study	9
P163 The role of pharmacists in cystic fibrosis care: preliminary results from a systematic review	9
EPS5.09Influencing factors of physical activity in youth with cystic fibrosis: a socio-ecological approach	9
P323 European practices in vitamin supplementation for cystic fibrosis since the introduction of CFTR modulators	9
WS09.01CFTR activity in nasal epithelia from subjects with different genotypes	9
P373 Does visualising lung function and Body mass index (BMI) trends using the ‘My report’ section on the cystic fibrosis registry database help clinical decision making and improve the patient experi	9
P333 Scoping review protocol: Diet composition and quality in children with cystic fibrosis in the modulator era	9
EPS1.05Sleep quality and mental health in children with cystic fibrosis: the impact of elexacaftor/tezacaftor/ivacaftor therapy	9
P139 Chronic production of IL-23 activates a functional heterogeneity of IL-17F-producing cells, which untangle the immunological signature in young adult cystic fibrosis patients with early ABPA diag	9
EPS6.07Correlation of responses in patient derived rectal organoids and clinical responses to modulators in people with CF homozygous for F508del-CFTR	9
P124 The role of forced oscillometry technique in monitoring lung function of paediatric cystic fibrosis patients on elexacaftor/tezacaftor/ivacaftor therapy	9
P205 Adult annual reviews at the West Midlands Adult cystic fibrosis Centre (WMACFC): a service improvement project	9
WS07.01‘Silent' lung disease progression in people receiving elexacaftor/tezcaftor/ivacaftor (ETI) therapy revealed by Oxygen Enhanced-MRI (OE-MRI) and Multiple breath washout with Short extension (MB	9
EPS2.06Exploring the diversity of nontuberculous mycobacteria in cystic fibrosis centers across the U.S.: Lessons from the prospective HALT study	9
536 Effect of elexacaftor-tezacaftor-ivacaftor on nutritional status and glucose metabolism in children and adolescents with cystic fibrosis	8
239 Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: A personalized approach	8
Manifestation and staging of arthropathy in cystic fibrosis. Defining different stages of cystic fibrosis arthropathy using ultrasound imaging and clinical scoring	8
339 Diagnostic dilemmas in cystic fibrosis screen–positive infants with F191V and low sweat chloride	8
P249 Awareness of the potential benefits of occupational therapy in a cystic fibrosis multidisciplinary team	8
530 Airway volatile organic compounds can achieve culture-independent identification of Nontuberculous mycobacteria in people with cystic fibrosis	8
357 Implementing a social determinants of health screener in a large pediatric cystic fibrosis center	8
266 Airway clearance therapy: experiences and perceptions of adults with cystic fibrosis	8
552 Using the TriNetX database to describe the prevalence of VTE and gastrointestinal disease in children with cystic fibrosis	8
1 High Ca++ does not hinder cyclic diguanosine monophosphate–mediated control of the Pseudomonas aeruginosa biofilm life cycle	8
Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis	8
412 Increasing the number of people with cystic fibrosis seen in outpatient clinic quarterly	8
414 National patterns of CF RISE uptake and engagement: a multidimensional approach to increase transition program utilization	8
235 Prevalence of colorectal neoplasia in adults with cystic fibrosis: A single-center experience	8
WS04.02 Clinical impact of pathogenic CFTR mutations in paediatric-onset pancreatitis (preliminary analysis from the APPLE study)	8
P299 Assessing dynamics of abdominal symptoms during a new therapy with elexacaftor/tezacaftor/ivacaftor using the new CFAbd-day2day© questionnaire	8
49 Bacterial siderophores drive cefiderocol resistance and crossprotection	8
72 Investigating polymicrobial interactions involving Streptococcus in the cystic fibrosis airway	8
Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant	8
Implementation of standardized cystic fibrosis care algorithm to improve the center data-quality improvement project international collaboration	8
102 Clinical Pseudomonas aeruginosa isolates from cystic fibrosis sinusitis prevent flagellin-mediated immune recognition	8
344 Unraveling the complexity of cystic fibrosis: genetic modifiers and their roles in cystic fibrosis pathogenesis	8
112 Calprotectin predicts cystic fibrosis pulmonary exacerbations in equivocal cases	8
154 In vitro responses of F508DEL human nasal epithelial cells correlate with clinical improvement with elexacaftor/tezacaftor/ivacaftor	8
434 In vitro evaluation of TAVT-135, an artificial pan-genotypic chloride ion transporter	8
349 Intestinal epithelial-specific Cftr knockout induces fecal dysbiosis and bowel inflammation in mice consuming anti-obstructive dietary regimens	7
84 Plasmids acquired during the course of cystic fibrosis infections cause extreme antibiotic resistance in Pseudomonas aeruginosa	7
P073 Clinical efficacy of CFTR modulator therapy in patients carrying the I1234V mutation	7
P259 Inevitability of treatment after culturing Mycobacterium abscessus complex (MABSC) in cystic fibrosis	7